2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).
Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses adjuvant therapy for elderly patients with HER2-positive or triple-negative breast cancer (TNBC).
There is a lot of age bias when it comes to treating elderly patients with breast cancer, explains Muss. It is important to assess elderly patients based on their functional reserve as opposed to simply their age.